Biomarker Changes during 20 Years Preceding Alzheimer's Disease
- PMID: 38381674
- DOI: 10.1056/NEJMoa2310168
Biomarker Changes during 20 Years Preceding Alzheimer's Disease
Abstract
Background: Biomarker changes that occur in the period between normal cognition and the diagnosis of sporadic Alzheimer's disease have not been extensively investigated in longitudinal studies.
Methods: We conducted a multicenter, nested case-control study of Alzheimer's disease biomarkers in cognitively normal participants who were enrolled in the China Cognition and Aging Study from January 2000 through December 2020. A subgroup of these participants underwent testing of cerebrospinal fluid (CSF), cognitive assessments, and brain imaging at 2-year-to-3-year intervals. A total of 648 participants in whom Alzheimer's disease developed were matched with 648 participants who had normal cognition, and the temporal trajectories of CSF biochemical marker concentrations, cognitive testing, and imaging were analyzed in the two groups.
Results: The median follow-up was 19.9 years (interquartile range, 19.5 to 20.2). CSF and imaging biomarkers in the Alzheimer's disease group diverged from those in the cognitively normal group at the following estimated number of years before diagnosis: amyloid-beta (Aβ)42, 18 years; the ratio of Aβ42 to Aβ40, 14 years; phosphorylated tau 181, 11 years; total tau, 10 years; neurofilament light chain, 9 years; hippocampal volume, 8 years; and cognitive decline, 6 years. As cognitive impairment progressed, the changes in CSF biomarker levels in the Alzheimer's disease group initially accelerated and then slowed.
Conclusions: In this study involving Chinese participants during the 20 years preceding clinical diagnosis of sporadic Alzheimer's disease, we observed the time courses of CSF biomarkers, the times before diagnosis at which they diverged from the biomarkers from a matched group of participants who remained cognitively normal, and the temporal order in which the biomarkers became abnormal. (Funded by the Key Project of the National Natural Science Foundation of China and others; ClinicalTrials.gov number, NCT03653156.).
Copyright © 2024 Massachusetts Medical Society.
Comment in
-
Frühester Biomarker für Alzheimer.MMW Fortschr Med. 2024 Oct;166(16):29. doi: 10.1007/s15006-024-4311-7. MMW Fortschr Med. 2024. PMID: 39322887 Review. German. No abstract available.
Similar articles
-
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2. Cochrane Database Syst Rev. 2017. PMID: 28328043 Free PMC article.
-
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4. Cochrane Database Syst Rev. 2014. PMID: 24913723 Free PMC article.
-
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.JAMA Netw Open. 2025 Jul 1;8(7):e2519919. doi: 10.1001/jamanetworkopen.2025.19919. JAMA Netw Open. 2025. PMID: 40638114 Free PMC article.
-
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8. Lancet Neurol. 2016. PMID: 27068280
-
Change points for dynamic biomarkers in the Alzheimer's disease pathological cascade: A 30-year cohort study.Alzheimers Dement. 2025 Aug;21(8):e70544. doi: 10.1002/alz.70544. Alzheimers Dement. 2025. PMID: 40741702 Free PMC article.
Cited by
-
Cognitive modeling of the Mnemonic Similarity Task as a digital biomarker for Alzheimer's Disease.bioRxiv [Preprint]. 2024 Mar 11:2024.03.07.584012. doi: 10.1101/2024.03.07.584012. bioRxiv. 2024. Update in: Alzheimers Dement. 2024 Oct;20(10):6935-6947. doi: 10.1002/alz.14163. PMID: 38559159 Free PMC article. Updated. Preprint.
-
Timing of biomarker changes preceding Alzheimer's disease: for diagnosis, treatment or prevention?Sci China Life Sci. 2025 Feb;68(2):575-577. doi: 10.1007/s11427-024-2733-7. Epub 2024 Oct 12. Sci China Life Sci. 2025. PMID: 39422811 No abstract available.
-
Predictive value of postoperative prognostic nutritional index trajectory for mortality outcomes after off-pump coronary artery bypass surgery: a retrospective cohort study.Front Nutr. 2025 May 7;12:1530651. doi: 10.3389/fnut.2025.1530651. eCollection 2025. Front Nutr. 2025. PMID: 40400705 Free PMC article.
-
Hearing and cognitive scores measured with the Montreal Cognitive Assessment Scale in The HUNT Study, Norway.Alzheimers Dement. 2025 Feb;21(2):e14514. doi: 10.1002/alz.14514. Epub 2025 Jan 23. Alzheimers Dement. 2025. PMID: 39846386 Free PMC article.
-
Polygenic Hazard Score for Predicting Age-associated Risk of Alzheimer's Disease in European Populations: Development and Validation.medRxiv [Preprint]. 2025 Jul 28:2025.07.28.25332293. doi: 10.1101/2025.07.28.25332293. medRxiv. 2025. PMID: 40766162 Free PMC article. Preprint.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials